Data / Drug companies / Patrin Pharma, Inc.
Patrin Pharma, Inc.: 24 products in the FDA NDC directory, labeler code 39328
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patrin Pharma, Inc. (labeler code 39328) lists 24 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 16 prescription drugs, 8 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on October 1, 2025.
The request: Watch Patrin Pharma, Inc. (FDA labeler code 39328): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 39328
- Products in commercial distribution
- 24
- Packages
- 39
- Finished drugs by generic name
- 13
- Prescription products
- 16
- Over the counter products
- 8
- Controlled substance products
- Schedule II 2, Schedule V 1
- Flagged as original packager
- 24 of 24 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- April 1, 2013
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 8 | 33.3% |
| Other unapproved drugs | 8 | 33.3% |
| Generic drugs (ANDA) | 8 | 33.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 16 | 66.7% |
| Over the counter drugs | 8 | 33.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Hyoscyamine sulfate | 4 | 24 |
| Sennosides | 3 | 65 |
| Acetaminophen | 3 | 214 |
| Hydrocortisone acetate | 2 | 35 |
| Methylphenidate hcl | 2 | 1 |
| Lidocaine | 2 | 216 |
| Pregabalin | 1 | 54 |
| Urea | 1 | 17 |
| Levetiracetam | 1 | 87 |
| Amantadine hydrochloride | 1 | 32 |
| Fluocinolone acetonide | 1 | 17 |
| Cyproheptadine hydrochloride | 1 | 24 |
| Calcitriol | 1 | 23 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 7 | 29.2% |
| Syrup | 3 | 12.5% |
| Liquid | 3 | 12.5% |
| Tablet | 3 | 12.5% |
| Cream | 3 | 12.5% |
| Suppository | 2 | 8.3% |
| Tablet, extended release | 1 | 4.2% |
| Tablet, orally disintegrating | 1 | 4.2% |
| Oil | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Urea 40% | 39328-019 | Cream | Other unapproved drugs | October 1, 2025 |
| Hyoscyamine Sulfate | 39328-052 | Tablet, extended release | Other unapproved drugs | August 16, 2024 |
| Hyoscyamine Sulfate | 39328-051 | Tablet | Other unapproved drugs | August 15, 2024 |
| Hyoscyamine Sulfate | 39328-050 | Tablet | Other unapproved drugs | August 15, 2024 |
| Hyoscyamine Sulfate | 39328-049 | Tablet, orally disintegrating | Other unapproved drugs | August 15, 2024 |
| Levetiracetam | 39328-511 | Solution | Generic drugs (ANDA) | January 31, 2024 |
| Acetaminophen Solution | 39328-034 | Liquid | Over the counter monograph drugs | October 16, 2023 |
| Senna UD | 39328-220 | Syrup | Over the counter monograph drugs | October 1, 2023 |
| Senna UD | 39328-120 | Syrup | Over the counter monograph drugs | October 1, 2023 |
| Senna | 39328-020 | Syrup | Over the counter monograph drugs | October 1, 2023 |
| Acetaminophen Solution | 39328-032 | Liquid | Over the counter monograph drugs | September 27, 2023 |
| Acetaminophen Solution | 39328-031 | Liquid | Over the counter monograph drugs | September 27, 2023 |
| Calcitriol | 39328-042 | Solution | Generic drugs (ANDA) | August 14, 2023 |
| Amantadine Hydrochloride | 39328-530 | Solution | Generic drugs (ANDA) | August 11, 2023 |
| Pregabalin | 39328-090 | Solution | Generic drugs (ANDA) | June 14, 2022 |
| Cyproheptadine Hydrochloride | 39328-544 | Solution | Generic drugs (ANDA) | February 15, 2022 |
| Hydrocortisone Acetate | 39328-129 | Suppository | Other unapproved drugs | January 1, 2022 |
| Hydrocortisone Acetate | 39328-029 | Suppository | Other unapproved drugs | January 1, 2022 |
| Methylphenidate HCl | 39328-154 | Solution | Generic drugs (ANDA) | April 23, 2020 |
| Methylphenidate HCl | 39328-054 | Solution | Generic drugs (ANDA) | April 23, 2020 |
| Lidocaine Anorectal | 39328-025 | Cream | Over the counter monograph drugs | November 1, 2018 |
| Lidocaine | 39328-024 | Cream | Over the counter monograph drugs | November 1, 2018 |
| Flac Otic Oil | 39328-079 | Oil | Generic drugs (ANDA) | April 12, 2018 |
| Prenatal Plus Vitamins | 39328-106 | Tablet | Other unapproved drugs | April 1, 2013 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.